Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Gastric Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 29 articles:
HTML format



Single Articles


    March 2024
  1. SALANI F, Vivaldi C, Rreka E, Genovesi V, et al
    Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Carcinomatosis: The Need for Clear Answers Through Proper Questions.
    J Clin Oncol. 2024 Mar 14:JCO2302611. doi: 10.1200/JCO.23.02611.
    PubMed    


    February 2024
  2. ZHU M, Yoon HH
    Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?
    J Clin Oncol. 2024;42:373-377.
    PubMed    


  3. GALLANIS AF, Gamble LA, Samaranayake SG, Lopez R, et al
    Costs of Cancer Prevention: Physical and Psychosocial Sequelae of Risk-Reducing Total Gastrectomy.
    J Clin Oncol. 2024;42:421-430.
    PubMed     Abstract available


    December 2023
  4. MOEHLER M, Xiao H, Blum SI, Elimova E, et al
    Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
    J Clin Oncol. 2023;41:5388-5399.
    PubMed     Abstract available


    November 2023
  5. LORENZEN S, Gotze TO, Thuss-Patience P, Biebl M, et al
    Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
    J Clin Oncol. 2023 Nov 14:JCO2300975. doi: 10.1200/JCO.23.00975.
    PubMed     Abstract available


  6. DEL RIVERO J, Perez K, Kennedy EB, Mittra ES, et al
    Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    J Clin Oncol. 2023;41:5049-5067.
    PubMed     Abstract available


    October 2023
  7. RAU B, Lang H, Koenigsrainer A, Gockel I, et al
    Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial.
    J Clin Oncol. 2023 Oct 31:JCO2202867. doi: 10.1200/JCO.22.02867.
    PubMed     Abstract available


  8. LEE CK, Kim HS, Jung M, Kim H, et al
    Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study.
    J Clin Oncol. 2023 Oct 26:JCO2300971. doi: 10.1200/JCO.23.00971.
    PubMed     Abstract available


    September 2023
  9. KIM CG, Jung M, Kim HS, Lee CK, et al
    Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer.
    J Clin Oncol. 2023;41:4394-4405.
    PubMed     Abstract available


    March 2023
  10. SHAH MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, et al
    Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
    J Clin Oncol. 2023;41:1470-1491.
    PubMed     Abstract available


    February 2023
  11. YAMAGUCHI K, Bang YJ, Iwasa S, Sugimoto N, et al
    Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
    J Clin Oncol. 2023;41:816-825.
    PubMed     Abstract available


    January 2023
  12. ANDRE T, Tougeron D, Piessen G, de la Fouchardiere C, et al
    Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
    J Clin Oncol. 2023;41:255-265.
    PubMed     Abstract available


    November 2022
  13. HOFHEINZ RD, Merx K, Haag GM, Springfeld C, et al
    FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
    J Clin Oncol. 2022;40:3750-3761.
    PubMed     Abstract available


    August 2022
  14. MARON SB, Moya S, Morano F, Emmett MJ, et al
    Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.
    J Clin Oncol. 2022;40:2458-2467.
    PubMed     Abstract available


    July 2022
  15. PATEL MA, Kratz JD, Lubner SJ, Loconte NK, et al
    Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice.
    J Clin Oncol. 2022 Jul 15:JCO2102500. doi: 10.1200/JCO.21.02500.
    PubMed     Abstract available


    June 2022
  16. GWEE YX, Chia DKA, So J, Ceelen W, et al
    Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis.
    J Clin Oncol. 2022 Jun 1:JCO2102745. doi: 10.1200/JCO.21.02745.
    PubMed     Abstract available


    March 2022
  17. KIM YW, Min JS, Yoon HM, An JY, et al
    Laparoscopic Sentinel Node Navigation Surgery for Stomach Preservation in Patients With Early Gastric Cancer: A Randomized Clinical Trial.
    J Clin Oncol. 2022 Mar 24:JCO2102242. doi: 10.1200/JCO.21.02242.
    PubMed     Abstract available


    February 2022
  18. ZHAO JJ, Yap DWT, Chan YH, Tan BKJ, et al
    Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
    J Clin Oncol. 2022;40:392-402.
    PubMed     Abstract available


    September 2021
  19. MO DC, Qin L, Ye LJ
    Neoadjuvant Docetaxel, Oxaliplatin, and S-1 in Resectable Advanced Gastric Cancer.
    J Clin Oncol. 2021 Sep 30:JCO2101528. doi: 10.1200/JCO.21.01528.
    PubMed    


  20. KANG YK, Yook JH, Park YK, Lee JS, et al
    PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
    J Clin Oncol. 2021;39:2903-2913.
    PubMed     Abstract available


    August 2021
  21. TEH SH, Uong S, Lin TY, Shiraga S, et al
    Clinical Outcomes Following Regionalization of Gastric Cancer Care in a US Integrated Health Care System.
    J Clin Oncol. 2021 Aug 2:JCO2100480. doi: 10.1200/JCO.21.00480.
    PubMed     Abstract available


    March 2021
  22. HAFFNER I, Schierle K, Raimundez E, Geier B, et al
    HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study.
    J Clin Oncol. 2021 Mar 25:JCO2002761. doi: 10.1200/JCO.20.02761.
    PubMed     Abstract available


  23. VAN DER VEEN A, Brenkman HJF, Seesing MFJ, Haverkamp L, et al
    Laparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA): A Multicenter Randomized Clinical Trial.
    J Clin Oncol. 2021;39:978-989.
    PubMed     Abstract available


  24. SHAH MA, Bodoky G, Starodub A, Cunningham D, et al
    Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1).
    J Clin Oncol. 2021;39:990-1000.
    PubMed     Abstract available


    January 2021
  25. LU Z, Fang Y, Liu C, Zhang X, et al
    Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial.
    J Clin Oncol. 2021 Jan 8:JCO2001254. doi: 10.1200/JCO.20.01254.
    PubMed     Abstract available


    November 2020
  26. MOEHLER M, Dvorkin M, Boku N, Ozguroglu M, et al
    Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100.
    J Clin Oncol. 2020 Nov 16:JCO2000892. doi: 10.1200/JCO.20.00892.
    PubMed     Abstract available


    July 2020
  27. CATENACCI DVT, Rasco D, Lee J, Rha SY, et al
    Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma.
    J Clin Oncol. 2020;38:2418-2426.
    PubMed     Abstract available


    June 2020
  28. MAKIYAMA A, Sukawa Y, Kashiwada T, Kawada J, et al
    Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
    J Clin Oncol. 2020;38:1919-1927.
    PubMed     Abstract available


    April 2020
  29. FUKUOKA S, Hara H, Takahashi N, Kojima T, et al
    Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
    J Clin Oncol. 2020 Apr 28:JCO1903296. doi: 10.1200/JCO.19.03296.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gastric Cancer is free of charge.